Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.39 |
| ▸ | PDE1A | P54750 | 3/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406946 | 0.89 | KEAP1 (0.40) | NR3C1HSD11B1LRRK2 | |
| SCHEMBL4718010 | 0.87 | PDE4B (0.45) | PDE4D | |
| SCHEMBL1407004 | 0.86 | HCAR3 (0.38) | NR3C1KDM4CHSD11B1 | |
| SCHEMBL1407026 | 0.86 | CNR2 (0.39) | NR3C1KDM4CHSD11B1 | |
| SCHEMBL1406962 | 0.84 | CNR2 (0.41) | NR3C1KDM4CHSD11B1S1PR1 | |
| SCHEMBL1406919 | 0.83 | LRRK2 (0.37) | NR3C1HSD11B1LRRK2 | |
| SCHEMBL1406924 | 0.83 | LRRK2 (0.37) | NR3C1HSD11B1LRRK2 | |
| SCHEMBL4717587 | 0.82 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL22684184 | 0.82 | TRPV4 (0.46) | KDM4CHSD11B1PDE1CPDE1APDE1B | |
| SCHEMBL1406858 | 0.80 | PDE4B (0.48) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999114-B1 | PYRAZOLES AS 11-BETA-HSD-1 | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2295411-A1 | Pyrazoles as 11-beta-hsd-1 | F. Hoffmann-La Roche AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1999114-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. Hoffmann-la Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107470-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | NR3C1 553/4885KDM4C 3911/4885PDE4D 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.